TITLE:
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

CONDITION:
Multiple Myeloma

INTERVENTION:
CDC-501

SUMMARY:

      The purpose of the study is to select the dose regimen of CDC-501 that provides the most
      promising evidence of efficacy.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  Subject must be diagnosed with multiple myeloma (with measurable M-Protein in serum
             and/or urine), and be considered to have disease progression after at least two
             cycles of treatment or have relapsed after treatment.

          -  Subject must understand and voluntarily sign an informed consent document.

          -  Subject must not have received corticosteroids, other chemotherapy, thalidomide, or
             other investigational agents, within 21 days of baseline

          -  ECOG (Zubrod) performance status of 0 to 2.

          -  Subject must be able to adhere to the study visit schedule and other protocol
             requirements.

          -  Women of childbearing potential (WCBP ) must have a negative serum or urine pregnancy
             test within 7 days of baseline. In addition, sexually active WCBP must agree to use
             adequate contraceptive methods (oral, injectable, or implantable hormonal
             contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with
             spermicide; or vasectomized partner) while on study drug.
      
